Cirrhosis: Difference between revisions
No edit summary |
|||
| Line 11: | Line 11: | ||
*[[liver disease induced coagulopathy|Coagulopathy]] | *[[liver disease induced coagulopathy|Coagulopathy]] | ||
*[[GI bleed]] | *[[GI bleed]] | ||
==Differential Diagnosis== | |||
*[[Hepatitis]] chronic B and C | |||
*Alcoholic liver disease | |||
*[[Non-alcoholic steatohepatitis]] | |||
*Drug induced (ie. [[Tylenol]]. [[amiodarone]], NRTIs]) | |||
*[[Congestive heart failure (CHF)|Cardiac Cirrhosis]] | |||
*Primary biliary cirrhosis | |||
*[[Primary sclerosing cholangitis]] | |||
*[[Autoimmune hepatitis]] | |||
*Alpha1 anti-trypsin Deficiency | |||
*[[Cystic Fibrosis]] | |||
==Management== | |||
'''Complications of cirrhosis''' | |||
*[[Ascites]] | |||
*Esophageal [[varices]] | |||
*[[Hepatic encephalopathy]] | |||
*[[Spontaneous bacterial peritonitis]] | |||
*[[Hepatorenal syndrome]] | |||
*Portal hypertension | |||
*[[Upper gastrointestinal bleed]] | |||
*[[Hepatocellular carcinoma]] | |||
'''Pain management in cirrhotic patients''' | |||
*[[Acetaminophen]] is safe for short-term use at reduced dose of 2 grams total per day | |||
*[[Gabapentin]] or [[pregabalin]] for neuropathic pain | |||
*Avoid [[NSAIDs]] | |||
*Avoid [[opioids]] | |||
**unpredictable effects if liver function impaired due to hepatic metabolism | |||
**if necessary, [[fentanyl]] or [[tramadol]] probably safest | |||
==Disposition== | |||
*Often complex and should be based on presence/absence of acute complications | |||
*If no complications present, discussion with patient's primary care provider or gastroenterologist recommended | |||
==Prognosis== | |||
===Child-Pugh Score[http://www.mdcalc.com/child-pugh-score-for-cirrhosis-mortality/ <ref>Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by CG Child. Philadelphia: Saunders 1964:50-64</ref>]=== | ===Child-Pugh Score[http://www.mdcalc.com/child-pugh-score-for-cirrhosis-mortality/ <ref>Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by CG Child. Philadelphia: Saunders 1964:50-64</ref>]=== | ||
| Line 47: | Line 84: | ||
| <9 || 1.9% | | <9 || 1.9% | ||
|} | |} | ||
==See Also== | ==See Also== | ||
Revision as of 16:31, 4 June 2020
Background
- A generally irreversible fibrotic scarring of the liver parenchyma resulting in liver failure
- The twelfth leading cause of death in men and women in 2013[1]
Clinical Features
- May be asymptomatic initially
- Malaise, weakness (from electrolyte derangements)
- Abdominal pain
- Ascites, SBP (fever, abdominal tenderness)
- Altered mental status due to hepatic encephalopathy
- Coagulopathy
- GI bleed
Differential Diagnosis
- Hepatitis chronic B and C
- Alcoholic liver disease
- Non-alcoholic steatohepatitis
- Drug induced (ie. Tylenol. amiodarone, NRTIs])
- Cardiac Cirrhosis
- Primary biliary cirrhosis
- Primary sclerosing cholangitis
- Autoimmune hepatitis
- Alpha1 anti-trypsin Deficiency
- Cystic Fibrosis
Management
Complications of cirrhosis
- Ascites
- Esophageal varices
- Hepatic encephalopathy
- Spontaneous bacterial peritonitis
- Hepatorenal syndrome
- Portal hypertension
- Upper gastrointestinal bleed
- Hepatocellular carcinoma
Pain management in cirrhotic patients
- Acetaminophen is safe for short-term use at reduced dose of 2 grams total per day
- Gabapentin or pregabalin for neuropathic pain
- Avoid NSAIDs
- Avoid opioids
Disposition
- Often complex and should be based on presence/absence of acute complications
- If no complications present, discussion with patient's primary care provider or gastroenterologist recommended
Prognosis
Child-Pugh Score[2]
| +1 | +2 | +3 | |
|---|---|---|---|
| Bilirubin | <2mg/dL | 2-3mg/dL | >3 Mg/dL |
| Albumin | >3.5mg/dL | 2.8-3.5mg/dL | <2.8mg/dL |
| INR | <1.7 | 1.7-2.2 | >2.2 |
| Ascites | No ascites | Ascites, medically controlled | Ascites, poorly controlled |
| Encephalopathy | No encephalopathy | Encephalopathy, medically controlled | Encephalopathy, poorly controlled |
- Score ≤ 7 = Class A = 100% and 85% one and two-year patient survival
- Score 7 - 9 = Class B = 80% and 60% one and two-year patient survival
- Score ≥ 10 = Class c = 45% and 35% one and two-year patient survival
MELD Score[3]
| MELD-Na Score | 3-month mortality |
|---|---|
| 40 | 71.3% |
| 30-39 | 52.6% |
| 20-29 | 19.6% |
| 10-19 | 6.0% |
| <9 | 1.9% |
See Also
External Links
References
- ↑ Heron M. Deaths: Leading Causes for 2013. Natl Vital Stat Rep 2016: 16;65(2):1-95.
- ↑ Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by CG Child. Philadelphia: Saunders 1964:50-64
- ↑ Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 Feb;33(2):464-70.